Reproductive Drugs

hezikry's version from 2015-08-06 20:25


Question Answer
MOA of leuprolideGnRh analog. agonist when used in pulsatile fashion, but antagonist (blocks FSH/LH release) when used in continuous fashion.
Clinical use of leoprolideinfertility (pulsatile), prostate cancer (continuous), uterine fibroids (continuous)
A/E of leuprolideantiandrogen, nausea, vomiting
MOA estrogensbind estrogen receptors.
Clinical use estrogenshypogonadism or ovarian failure, hormone replacement therapy in postmenopausal women (must give with progesterone)
A/E estrogensincreased risk of endometrial cancer. metabolized by CYP450 inducers.
MOA of clomipheneantagonist at estrogen receptors in hypothalamus.
Clinical use of clomipheneused to treat infertility due to anouvlation. can use in PCOS In PCOS tonically increased LH leads to hyperproduction of androgens converted to estrogen. increased estrogen inhibits FSH.
A/E of clompihenemay cause hot flashes, ovarian enlargement, multiple pregnancies
MOA of tamoxifenantagonist at breast; agonist at bone of estrogen receptors. Agonist in endometrium
Clinical use of tamoxifenUsed to treat and prevent recurrent of ER/PR + breast cancer
A/E of tamoxifenincreases risk of thromboembolitc events and endometrial cancer
MOA of raloxifeneantagonist at breast, uterus; agonist at bone.
Clinical use of raloxifenetreat osteoporosis
A/E of raloxifeneIncreased risk of thromboemolic events but not endometrial cancer
Anastrozole/Exemestane MOAAromatase inhibitors used in postmenopausal women. Decreased conversion of testosterone to estrogen
Clinical use of anastrozole/exemestane Postmenopausal women with ER positive breast cancer
Progestins MOABind progesterone receptors
Clinical use of progestins decrease growth and increase vascularization in endometrium
A/E of progestinsirregular bleeding
Mifepristone MOAcompetitive inhibitor of progestins at progesterone inhibitor
Clinical use of MifepristoneTermination of pregnancy
A/E of mifepristoneheavy bleeding
MOA of OCPSestrogens and progestins inhibit LH/FSH and thus prevent estrogen surge. No estrogen surge, no LH surge,no ovulation.
A/E of OCPScontraindications smokers older than 35, patients with history thromboembolism, estrogen dependent tumors
MOA of terbutalineB2 agonists that relax the uterus. Usted to decrease contraction frequency in women during labor.
A/E of terbutalinetachycardia, hypotension, pulmonary edema
MOA of danazolsynthetic androgen that acts as a partial agonist at androgen receptors
Clinical use of danazol endometriosis, hereditary angioedema, fibrocystic breast disease
A/E of danazolhot flashes, weight gains, hirsutism.


Question Answer
MOA of testosteroneagonist at androgne receptor
Clinical use of testosteroneHypogonadism and promotes development of secondary se characteristics. ER + breast cancer
A/E of testosteronemasculinization in females. decreases intratesticular testosterone in males by inhibiting release of LH. Premature closure of epiphyseal plates. Increase in LDL, decrease in HDL. Shuts down sertoli cell spermatogenesis, but reversible.
MOA of finasteride5 alpha reductase inhibitor
Clinical use of finasterideBPH and male pattern baldess
MOA of flutamidea nonsteroidal competitive inhibitor at androgen receptors.
Clinical use of flutamideused for prostate carcinoma.
MOA of ketoconazoleinhibits steroid synthesis
clinical use of ketoconazole and spironolactonePCOS reduce androgenic symptoms
MOA of spironolactoneinhibits steroid binding
MOA of tamsulosinalpha 1 antagonist
Clinical use of tamsulosinBPH
MOA of slidenafil, vardenafil, tadafil inhibits PDE5 and increases cGMP, smooth muscle relaxation in corpus cavernosum, increases blood flow and erection
Clinical use of slidenafil, vardenafil, tadafil erecticle dysfunction, reynaud's, primary pulmonary HTN
A/E slidenafil, vardenafil, tadafil risk of life threatening hypotension in patients taking nitrates
MOA of minoxidildirect arteriolar vasodilator
Clinical use of minoxidilandrogenic alopecia; severe refractory hypotension
Preferred initial therapy to treat BPHalpha antagonists (zosins) work within days to weeks
Preferred therapy to reduce prostate volume5-alpha-reductase inhibitors
name all the drugs for prostate cancer5 alpha reductase inhibitors, leuprolide and flutamide, testosterone receptor blocker, ketoconazole, spironolactone